With the strengthening of China's economic and technological capabilities, the research and development of new drugs will inevitably aim for higher goals, achieving a new historical transformation. This transition will progress from "imitative innovation and replication-style creativity" towards a new phase of original innovation.

The source of original innovation lies in fundamental research, where scientists can infuse vitality into this wellspring. ZSHK will actively engage with universities, research institutions, and scientists face-to-face. We will address the pain points and difficulties encountered in pharmaceutical innovation, from basic research to PCC to IND. By analyzing these challenges, sharing case experiences, and collaboratively devising solutions, we aim to assist scientists in tackling research and development challenges, ultimately contributing to original innovation.

Dr. Li Ming, CEO of ZSHK, has been invited to deliver a keynote speech on "Key Factors in Early Drug-like Properties Evaluation of Chemical Compounds" at the MacauU on June 2, 2023. During the event, esteemed guests will discuss strategies for addressing challenges in drug development and enhancing the success rate of pharmaceutical development.